Accessibility Menu
MiNK Therapeutics logo

MiNK Therapeutics(NASDAQ) INKT

Market Cap$52.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-91%
5 YearN/A
1 Year-31%
1 Month-8%
$10.56
+0.57%
+0.06Today
After hours$10.55-$0.01 (-0.10%)
MiNK Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 10.502026-07-31
MiNK Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.15%USD 11.072026-07-24
1 month-8.38%USD 11.462026-07-01
3 month-9.56%USD 11.612026-05-01
Year to date-5.83%USD 11.152025-12-31
1 year-30.74%USD 15.162025-07-31
3 year-39.31%USD 17.302023-08-01
Since inception-91.25%USD 120.002021-10-15

MiNK Therapeutics Financials at a Glance

Market Cap

$52.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.47M

EPS (TTM)

-$2.84

P/E Ratio

-3.70

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$10.56

Volume

5,614.284

Open

$10.48

Previous Close

$10.69

Daily Range

$10.48 - $10.75

52-Week Range

$8.48 - $18.17

Estimated Earnings Date

Aug 13, 2026

INKT News

featured-earnings-leadership-highlights.png

MiNK Therapeutics Extends Cash Runway

Motley Fool Markets TeamAug 14, 2025
Foolcom-Featured.png

MiNK Therapeutics Cuts Q2 Cash Use 31%

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MiNK Therapeutics

MiNK develops cell therapies to help treat cancer and immune diseases. Its main products aim to support patients with hard-to-treat conditions. These therapies use donor cells to target disease without needing custom solutions for each patient.

Cell Therapy Lineup: What’s in the MiNK Toolbox?

  • AGENT-797: Off-the-shelf cell therapy for cancer and severe lung diseases; in clinical trials. (0% of revenue; pre-commercial)
  • MiNK-413: Engineered cell therapy targeting blood cancers; in preclinical development. (0% of revenue)
  • MiNK-215: Cell therapy targeting tumor-supporting cells; in early studies. (0% of revenue)
  • Bispecific iNKT Engagers: Therapies designed to help immune cells find and attack tumors. (0% of revenue)
  • Personalized Neoantigen Library: Custom therapies for unique tumor markers in individual patients. (0% of revenue)

Growth Moves: MiNK’s Expansion Playbook

  • Launched as a subsidiary of Agenus in 2017; IPO in 2021.
  • Advanced AGENT-797 to Phase 2 trials for cancer and lung conditions in 2024-2025.
  • Started new clinical trial for gastroesophageal cancers in 2024.
  • Formed partnerships with C-Further, Autonomous Therapeutics, and Immunoscape for research and technology.
  • Expanded pipeline with new cell therapy candidates and manufacturing upgrades since 2023.

What Makes MiNK Stand Out in the Crowd?

MiNK uses donor immune cells, so treatments are ready-made and not patient-specific. Its therapies combine two types of immune responses, aiming for broader disease coverage. The company’s automated manufacturing process supports consistent quality and potential cost savings.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Operating loss was $12.6 million in 2025, up 12.0% from 2024.
  • R&D expense was $5.8 million in 2025, down 9% from 2024.
  • Cash and equivalents were $13.4 million as of December 31, 2025.

Bottom Line

MiNK remains focused on developing cell therapies for cancer and immune diseases. The company faces ongoing losses but continues to expand its pipeline and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

15

CEO

Jennifer S. Buell, PhD

Website

www.minktherapeutics.com

Headquarters

New York City, NY 10010, US

INKT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

76.02%

Return on Capital

N/A

Return on Assets

-120.17%

Earnings Yield

-27.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$52.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.98M

Volume

5.61K

Avg. Volume

27.21K

Financials (TTM)

Gross Profit

-$167.05K

Operating Income

-$12.84M

EBITDA

-$12.30M

Operating Cash Flow

-$6.32M

Capital Expenditure

-$3.00

Free Cash Flow

-$6.32M

Cash & ST Invst.

$9.53M

Total Debt

$0.00

MiNK Therapeutics Performance Analysis

MiNK Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
MiNK Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
MiNK Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -8.31-7.9%
20232023-12-31USD -6.54-21.4%
20242024-12-31USD -2.86-56.3%
20252025-12-31USD -2.932.4%
MiNK Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-51.4%
Q32025-09-3038.7%
Q42025-12-3115.4%
Q12026-03-31-3.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$36.07K

+29.0%

Gross Margin

0.00%

N/A

Market Cap

$52.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.49M

N/A

Employees

15

N/A

Net Income

-$2.74M

+0.9%

EBITDA

-$2.71M

+0.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$9.53M

+194.5%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.20%

N/A

Return on Invested Capital

-4.15%

N/A

Free Cash Flow

-$1.73M

+99.9%

Operating Cash Flow

-$1.73M

+99.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRXPNRx Pharmaceuticals, Inc.
$3.24+2.86%
SPRBSpruce Biosciences, Inc.
$43.14+0.72%
OTLKOutlook Therapeutics, Inc.
$0.91-6.51%
GANXGain Therapeutics, Inc.
$1.75+4.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About INKT

What is the current price of MiNK Therapeutics?

MiNK Therapeutics is trading at $10.69 per share.

What is the 52-week range for MiNK Therapeutics?

Over the past 52 weeks, MiNK Therapeutics has traded between $8.48 and $18.17.

How much debt does MiNK Therapeutics have?

As of the most recent reporting period, MiNK Therapeutics reported total debt of $0.00.

How much cash does MiNK Therapeutics have on hand?

MiNK Therapeutics reported $9.53M in cash and cash equivalents in its most recent financial results.

What is MiNK Therapeutics’s dividend yield?

MiNK Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services